Yahoo Web Search

Search results

1. • • Janet Woodcock is the FDA’s Principal Deputy Commissioner. In this role she works closely with the Commissioner of Food and Drugs to develop and implement key public health initiatives and helps oversee the agency’s day-to-day functions. She served as the Acting Commissioner of Food and Drugs from Jan. 20, 2021 until Feb. 17, 2022.
     www.fda.gov › about-fda › fda-organization

     Janet Woodcock | FDA - U.S. Food and Drug Administration

2. People also ask

   Will FDA regulator Janet Woodcock retire in 2024?

   • WOODCOCK SET TO RETIRE — Longtime FDA regulator Janet Woodcock, who has worked at the agency since 1986, plans to retire in early 2024, FDA Commissioner Robert Califf told agency staff Thursday. Califf’s all-hands email to FDA staff came hours after POLITICO first reported the news of Woodcock’s retirement plans.

   Woodcock to depart FDA after nearly four-decade career

   www.politico.com/newsletters/prescription-pulse/2023/11/17/woodcock-to-depart-fda-after-nearly-four-decade-career-00127748

   See all results for this question

   When did Susan Woodcock join the FDA?

   • Woodcock joined the FDA in 1986, first having several roles at the agency’s Center for Biologics Evaluation and Research, which regulates vaccines, blood products and products derived from living tissues like cell and gene therapies. In 1994, she joined the drug evaluation and review division as director.

   Top FDA official Woodcock to retire early next year

   www.biopharmadive.com/news/fda-janet-woodcock-retirement-califf/700110/

   See all results for this question

   When did Dr Woodcock become FDA Deputy Commissioner?

   • In 2004, Dr. Woodcock became the FDA’s Deputy Commissioner and Chief Medical Officer. Later she took on other executive leadership positions in the Commissioner’s Office, including Deputy Commissioner for Operations and Chief Operating Officer.

   Janet Woodcock | FDA - U.S. Food and Drug Administration

   www.fda.gov/about-fda/fda-organization/janet-woodcock

   See all results for this question

   Why did Elizabeth Woodcock criticize Sarepta Therapeutics?

   • Near the end of the Obama administration, Woodcock faced criticism for her support of Sarepta Therapeutics’ drug for Duchenne muscular dystrophy, which was approved despite opposition from FDA staff reviewers.

   Woodcock to depart FDA after nearly four-decade career

   www.politico.com/newsletters/prescription-pulse/2023/11/17/woodcock-to-depart-fda-after-nearly-four-decade-career-00127748

   See all results for this question

3. www.fda.gov › fda-organization › janet-woodcockJanet Woodcock | FDA - U.S. Food and Drug Administration

   www.fda.gov › fda-organization › janet-woodcock

   • Cached

   Feb 17, 2022 · She served as the Acting Commissioner of Food and Drugs from Jan. 20, 2021 until Feb. 17, 2022. Dr. Woodcock began her FDA career in 1986 at the Center for Biologics Evaluation and Research...

   • Occupation: Principal Deputy Commissioner

   • Works For: Office of The Commissioner

4. en.wikipedia.org › wiki › Janet_WoodcockJanet Woodcock - Wikipedia

   en.wikipedia.org › wiki › Janet_Woodcock

   • Cached

   Janet Woodcock (born August 29, 1948) is an American physician serving as Principal Deputy Commissioner of Food and Drugs, having previously served as Acting Commissioner of the U.S. Food and Drug Administration (FDA).

5. www.fda.gov › about-fda › fda-organizationFDA Leadership Profiles | FDA - U.S. Food and Drug Administration

   www.fda.gov › about-fda › fda-organization

   • Cached

   Oct 3, 2023 · FDA Leadership Profiles. Share. Commissioner of Food and Drugs. Robert M. Califf M.D., MACC. Principal Deputy Commissioner. Janet Woodcock, M.D. Chief Counsel. Mark Raza. Chief Financial Officer.

   • 
   • 
   • 
   • 

6. Videos

   • 

     11:49

     youtube.com

     Janet Woodcock, FDA, on future innovation in drug development

     Oct 1, 2018

     1.6K Views

   • 

     18:56

     youtube.com

     2021 REdI Conference Keynote Address by Janet Woodcock, MD

     Jul 28, 2021

     1K Views

   • 

     6:35

     youtube.com

     Janet Woodcock, Director CDER FDA on NORD Registry Program

     Oct 1, 2018

     2K Views

   View all

7. www.biopharmadive.com › news › fda-janet-woodcockTop FDA official Woodcock to retire early next year

   www.biopharmadive.com › news › fda-janet-woodcock

   • Cached

   Nov 16, 2023 · Win McNamee via Getty Images. Janet Woodcock, a top Food and Drug Administration official who had been on the short list to head the agency under President Joe Biden, will retire in early 2024 after 37 years at the regulator.

8. www.fdanews.com › articles › 212921-guest-columnGuest Column: Woodcock Leaves a 40-Year Legacy of ...

   www.fdanews.com › articles › 212921-guest-column

   • Cached

   Nov 30, 2023 · November 30, 2023. Wayne Pines, Senior Director at APCO Worldwide, a former associate commissioner of the FDA, and a member of the FDAnews Editorial Board, offers his perspective on the extraordinary career of the FDA’s Principal Deputy Commissioner Janet Woodcock, who will retire in early 2024.

9. www.politico.com › newsletters › prescription-pulseWoodcock to depart FDA after nearly four-decade career

   www.politico.com › newsletters › prescription-pulse

   • Cached

   Nov 17, 2023 · WOODCOCK SET TO RETIRE — Longtime FDA regulator Janet Woodcock, who has worked at the agency since 1986, plans to retire in early 2024, FDA Commissioner Robert Califf told agency staff...

10. www.statnews.com › 2024/01/30 › janet-woodcock-fdaWoodcock on FDA’s accelerated approval and her next chapter

    www.statnews.com › 2024/01/30 › janet-woodcock-fda

    • Cached

    Jan 30, 2024 · Janet Woodcock joined the FDA’s biologics division in 1986 but soon moved to the drug side, where over nearly three decades, she oversaw hundreds of reviews, new and evolving classes of...